Anebulo Pharmaceuticals Stock Forecast, Price & News

+0.20 (+2.75 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume924 shs
Average Volume4,582 shs
Market Capitalization$174.12 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ANEB News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.70 out of 5 stars

Medical Sector

917th out of 2,226 stocks

Pharmaceutical Preparations Industry

448th out of 870 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Anebulo Pharmaceuticals (NASDAQ:ANEB) Frequently Asked Questions

Is Anebulo Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Anebulo Pharmaceuticals stock.
View analyst ratings for Anebulo Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Anebulo Pharmaceuticals?

Wall Street analysts have given Anebulo Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Anebulo Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Anebulo Pharmaceuticals' next earnings date?

Anebulo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, September 20th 2021.
View our earnings forecast for Anebulo Pharmaceuticals

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) announced its quarterly earnings results on Sunday, June, 20th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.65.
View Anebulo Pharmaceuticals' earnings history

What price target have analysts set for ANEB?

1 brokerages have issued 1-year price objectives for Anebulo Pharmaceuticals' shares. Their forecasts range from $15.00 to $15.00. On average, they expect Anebulo Pharmaceuticals' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 101.1% from the stock's current price.
View analysts' price targets for Anebulo Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Anebulo Pharmaceuticals' key executives?

Anebulo Pharmaceuticals' management team includes the following people:
  • Dr. Joseph F. Lawler, Founder & Chairman (Age 48)
  • Dr. Daniel Schneeberger M.B.A., M.D., CEO & Director (Age 36)
  • Mr. Rex Merchant CFA, Chief Financial Officer (Age 61)
  • Dr. Linda Klumpers Ph.D., Chief Scientific Officer

Who are some of Anebulo Pharmaceuticals' key competitors?

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

What is Anebulo Pharmaceuticals' stock symbol?

Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB."

When did Anebulo Pharmaceuticals' quiet period expire?

Anebulo Pharmaceuticals' quiet period expired on Wednesday, June 16th. Anebulo Pharmaceuticals had issued 3,000,000 shares in its public offering on May 7th. The total size of the offering was $21,000,000 based on an initial share price of $7.00. During Anebulo Pharmaceuticals' quiet period, insiders and any underwriters that worked on the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anebulo Pharmaceuticals' stock price today?

One share of ANEB stock can currently be purchased for approximately $7.46.

How much money does Anebulo Pharmaceuticals make?

Anebulo Pharmaceuticals has a market capitalization of $174.12 million.

How many employees does Anebulo Pharmaceuticals have?

Anebulo Pharmaceuticals employs 2 workers across the globe.

What is Anebulo Pharmaceuticals' official website?

The official website for Anebulo Pharmaceuticals is

How can I contact Anebulo Pharmaceuticals?

The company can be reached via phone at 512-598-0931 or via email at [email protected]

This page was last updated on 8/3/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.